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RANKL (receptor activator of NF-B ligand) induces oste-
oclastogenesis by activatingmultiple signalingpathways in oste-
oclast precursor cells, chief among which is induction of long
lasting oscillations in the intracellular concentration of Ca2
([Ca2]i). The [Ca2]i oscillations activate calcineurin, which
activates the transcription factor NFATc1. The pathway by
which RANKL induces [Ca2]i oscillations and osteoclastogen-
esis is poorly understood. Here we report the discovery of a
novel pathway induced by RANKL to cause a long lasting
increase in reactive oxygen species (ROS) and [Ca2]i oscilla-
tions that is essential for differentiationof bonemarrow-derived
monocytes into osteoclasts. The pathway includes RANKL-me-
diated stimulation of Rac1 to generate ROS, which stimulate
phospholipase C1 to evoke [Ca2]i oscillations by stimulating
Ca2 release from the inositol 1,4,5-trisphosphate pool and
STIM1-regulated Ca2 influx. Induction and activation of the
pathway is observed only after 24-h stimulation with RANKL
and lasts for at least 3days.Thephysiological role of thepathway
is demonstrated in mice with deletion of the Peroxiredoxin II
gene and results in a mark increase is ROS and, consequently, a
decrease in bone density. Moreover, bone marrow-derived
monocytes inPrxII/primary culture show increasedROSand
spontaneous [Ca2]i oscillations. These findings identify the
primary RANKL-stimulated pathway to trigger the late stages of
osteoclastogenesis and regulate bone resorption.
Bone is a dynamic tissue that is constantly being remod-
eled. The remodeling process is a delicate balance between
the activities of osteoblasts and osteoclasts. Interference
with this balance results in serious human pathologies that
affect bone integrity. Tipping the balance in favor of oste-
oclasts leads to pathological bone resorption, which is
observed in autoimmune arthritis, osteoporosis, and peri-
odontitis (1, 2).
Bone marrow-derived monocyte/macrophage precursor
cells (BMM)2 of a hematopoietic origin develop into osteoclasts
through cell-to-cell signaling with mesenchymal cells, such as
osteoblasts (3, 4). Cell-to-cell interaction between the oste-
oclast precursors and osteoblastic/stromal cells are also essen-
tial for the differentiation of osteoclast progenitor cells into
mature osteoclasts (5, 6). RANKL (receptor activator of NF-B
ligand) is expressed in osteoblastic/stromal cells and is vital for
osteoclast differentiation (7–11). Stimulation of the RANK
receptor by RANKL in the presence of themacrophage colony-
stimulating factor (M-CSF) causes osteoclast differentiation
and activation in vitro (6, 8, 12). Moreover, the binding of
RANKL to its receptor results in the recruitment of the TNF
receptor-associated factor (TRAF) family of proteins, e.g.
TRAF6, which are linked to the NF-B and JNK pathways (13–
15). Of particular importance, a series of signals following
RANK activation induce oscillations in the free intracellular
concentration of Ca2 ([Ca2]i), which trigger the late stage of
osteoclast differentiation by activating the nuclear factor of
activatedT cells type c1 (NFATc1) (16). Unique aspects of these
RANKL-stimulated Ca2 oscillations is that they are observed
only 24–48 h post-stimulation, indicating the need for induc-
tion of the pathway responsible for the Ca2 oscillations. The
nature of this pathway and how it is induced are not known.
Ca2 is a ubiquitous intracellular messenger that mediates a
wide variety of cellular functions and is involved in the funda-
mental cellular processes of proliferation, differentiation, and
programmed cell death (17). In the case of osteoclast differen-
tiation, Ca2 plays an important role by sequentially activating
calcineurin andNFATc1 (16).Members of theNFAT family are
among the most strongly induced transcription factors follow-
ing RANKL stimulation. During osteoclastogenesis, costimula-
tory signals mediated by the immunoreceptor tyrosine-based
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activation motif and the activation of phospholipase C1
(PLC1) are involved in RANKL-induced [Ca2]i oscillations
and activation of NFATc1 (18). The tyrosine kinases Btk and
Tec are also involved in the activation of PLC1 by linking the
RANK and immunoreceptor tyrosine-based activation motif
signals (19). However, the signals upstream and downstream of
PLC1 that are stimulated by RANKL to generate [Ca2]i oscil-
lations and the mechanism for generation of the [Ca2]i oscil-
lations are not known.
We report here the discovery of a novel redox pathway acti-
vated by RANKL that is upstream of PLC1 and is essential for
RANKL-induced [Ca2]i oscillations and osteoclastogenesis.
This study originated with the observation that mice with
knock-out of peroxiredoxin II (PrxII), a thiol-based peroxide
reductase that clears cellular H2O2, develop severe bone loss
and osteoporosis. We were able to track the phenotype to
altered long term RANKL-generated reactive oxygen species
(ROS) and consequently osteoclast differentiation. ROS,
including the superoxide anion (O2. ) and H2O2, are well recog-
nized secondmessengers that participate in a variety of cellular
functions (20). Through the use of BMMs inwild type and PrxII
knock-out mice and through genetic and pharmacological
manipulation of Rac1, PrxII, PLC1, Ca2 release from stores,
and the store-operated Ca2 influx channel (SOC) regulator
stromal interactingmolecule 1 (STIM1), we identified the path-
way induced by RANKL to generate Ca2 oscillations and reg-
ulate osteoclastogenesis and bone metabolism.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents—RAW264.7 (Korean Cell Line
Bank, South Korea) and primary cultured BMMs were main-
tained in Dulbecco’s modified Eagle’s medium (Invitrogen) and
-minimum essential medium supplemented with 10% fetal
bovine serum (Invitrogen) and incubated in 5% CO2. To main-
tain BMMs, -minimum essential medium was supplemented
with 50 ng/ml M-CSF. Receptor activator of RANKL and
M-CSF were purchased from KOMA Biotech (South Korea).
Fura-2/AM was purchased from Teflabs (Austin, TX). Xesto-
spongin C (Xest C), gadolinium chloride (Gd3), U73122,
U73343, 2,7-dichlorofluorescein diacetate, diphenylene iodo-
nium (DPI), and N-acetyl-L-cysteine (NAC) were from Sigma-
Aldrich. The STIM1–1140 RNA interference and scramble
RNA interference were purchased from Dharmacon (Thermo
Fisher Scientific, Lafayette, CO). Polyclonal antibody for
phospho-PLC1 (p-PLC1, Tyr783) was from Millipore (Bil-
lerica, MA). Monoclonal antibodies for NFATc1 and plasma
membrane Ca2 ATPase (PMCA-5F10) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA) and Affinity Biore-
agents (Golden, CO), respectively. Monoclonal antibodies for
PLC1 and p-SUPER-PLC1 siRNAwere generous gifts fromDr.
YunSooBae (EwhaUniversity, Seoul, SouthKorea). ThePrxII/
mice (21)wereprovidedbyDr.SangWonKang(EwhaUniversity).
Preparation of BMMs—The femur and tibia were removed
from4–6-week-oldmice. The cells derived from the bonemar-
row of femur and tibia were collected and cultured in -mini-
mum essential medium containing 10% fetal bovine serum and
10 ng/ml M-CSF. The following day, nonadherent cells were
collected and seeded in 6-well plates and treated with M-CSF
(50 ng/ml). After 2 days the nonadherent cells werewashed out,
and the adherent cells were used as BMMs.
DNA/siRNA Transfection—Approximately 1–5  105 cells
were seeded on a 35-mm dish and incubated in antibiotic-free
medium, and after 24 h, the cells were replated. Plasmids in
250 l of Lipofectamine 2000 (Invitrogen) were diluted with
250 l of Opti-MEM. The mixtures were incubated for 20
min at room temperature before adding the cell. siRNA-trans-
fected cells were assayed by reverse transcription-PCR and
compared with cells transfected with scrambled siRNA. Green
fluorescent protein-positive cells were identified and used for
[Ca2]i measurements.
[Ca2]i Measurement—The cells were seeded on cover glass
in a 35-mm dish (5  104 cells/coverslip) and stimulated with
RANKL (50 ng/ml) for the indicated times. When necessary,
cells were pretreated with the required agents (U73122,
U73343,XestC,Gd3, NAC, andDPI), and the agentswere also
included in the perfusate. The cells were incubated with 5 M
Fura-2/AM for 40 min at room temperature and washed with
bath solution (140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM
HEPES, 1 mM CaCl2, 10 mM glucose, 310 mOsm, pH 7.4). The
coverslips were transferred to a perfusion chamber, and the
cells were continuously perfused with prewarmed (37 °C) bath
solution. Fura-2 fluorescence intensity was measured using
excitation wavelengths of 340 and 380 nm, and the emitted
fluorescence at 510 nm (Ratio  F340/F380) was monitored
using a CCD camera (Universal Imaging Co., Downingtown,
PA). The images were digitized and analyzed by MetaFluor
software (Universal Imaging).
Detection of GTP-bound Rac1—RAW264.7 cells were stimu-
lated with RANKL (50 ng/ml) for the indicated times. The cells
were lysed with ice-cold lysis buffer (50 mM Tris, pH 7.4, 100
mM NaCl, 2 mM MgCl2, 10% glycerol, 1% Nonidet P-40, 1 mM
dithiothreitol, and protease inhibitor cocktail (Sigma-Aldrich)).
Whole cell lysates were then incubated with 10 g of glutathi-
one S-transferase-CRIB (Cdc42 and Rac interaction binding
region) overnight at 4 °C. The following day, the cell lysates
were centrifuged for 5 min at 13,000 rpm, and the supernatant
was incubatedwith glutathione-Sepharose beads for 2 h at 4 °C.
The beads were washed with washing buffer (50 mM Tris, pH
7.4, 100 mM NaCl, 2 mM MgCl2, 10% glycerol, 1% Nonidet P-40,
1 mM dithiothreitol), and the bound proteins were eluted in
Laemmli sample buffer and separated by 15% SDS-PAGE.
Monoclonal antibody for Rac1 was used to detect GTP-bound
Rac1.
TRAP Staining—BMMs were seeded in 48-well plates at a
density of 2  104 cells/well and pretreated with the indicated
compounds. The cells were then stimulated with RANKL (50
ng/ml) supplemented with M-CSF. Six days later osteoclasto-
genesis was confirmed by TRAP staining. Cytochemical staining
of TRAP-positive cells was with the leukocyte acid phosphate
assay kit (Sigma-Aldrich), following the manufacturer’s proce-
dure. TRAPmultinucleated (3nuclei) cellswere then counted.
Measurement of Intracellular Reactive Oxygen Species—The
cells were seeded in 35-mm dishes at a density of 5  104.
Confluent cells were washedwithHanks’ balanced salt solution
and incubated for 5min in the dark at 37 °C in the same solution
containing 5 M 2,7-dichlorofluorescin diacetate. The cells
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were then examinedwith a laser-scanning confocalmicroscope
(model LSM510; Carl Zeiss) equippedwith an argon laser. Four
fields were randomly selected from each sample, and the mean
relative fluorescence intensity for each field wasmeasured with
a Zeiss vision system and averaged. All of the experiments were
repeated at least four times.
Western Blot—Whole cell lysates were prepared by extract-
ing cells with radioimmune precipitation assay lysis buffer
(20 mM Tris, pH 7.4, 250 mM NaCl, 2 mM EDTA, pH 8.0,
0.1% Triton X-100, 0.01 mg/ml aprotinin, 5 g/ml leupeptin,
0.4 mM phenylmethylsulfonyl fluoride, and 4 mM NaVO4),
and the extracts were spun at 12,000 rpm for 10 min to remove
insoluble material. Cleared extracts
(50100 g of protein/well) were
subjected to 6–12% SDS-PAGE,
and the proteins were electrotrans-
ferred to a nitrocellulose mem-
brane, blocked with 6% skimmed
milk, and probed with antibodies
against p-PLC1 (1:1000), PLC1
(1:3000), and Rac1 (1:1000). The
blots were washed, exposed to
horseradish peroxidase-conjugated
secondary antibodies for 1 h, and
detected by chemiluminescence
(Amersham Biosciences).
Analysis of Bone Density and
Skeletal Morphology—Femur and
tibia were removed from WT
and PrxII/ mice. To exclude dif-
ferences caused by threshold reso-
lution set-up, samples fromWTand
PrxII/ were set in one polysty-
rene holder. Bone density was then
measured with a three-dimensional
Micro-CT (SkyScan-1076 high res-
olution in vivo micro-CT system;
SkyScan, Aartselaar, Belgium) and
analyzed with CTAn and Cone
beam reconstruction software. His-
tological examination was per-
formed as described elsewhere (22,
23).
Dynamic Histomorphometry of
Bone Formation—Dynamic histo-
morphometric method was as
described before (24) with several
modifications. Briefly, 4-week-old
male mice were injected twice with
calcein (15 mg/kg intraperitoneally)
2 days apart. The animals were sac-
rificed on day 4, and undeclacified
bones were embedded in methyl
methacrylate. Longitudinal sections
(10-m thickness) of the tibiae were
prepared, and new bone formation
was assessed by confocal micros-
copy of calcein green.
Statistics—The results are expressed as the means  S.E.
from at least three independent experiments. The statistical
significances of differences between groups were determined
using Student’s t test (, p 0.05; *, p 0.01; **, p 0.005).
RESULTS
Spontaneous Increase of ROS in PrxII/ BMMs Causes
Induction of Autonomous [Ca2]i Oscillations andaDecrease of
Bone Density in PrxII/Mice—PrxII is a thiol-based peroxide
reductase that clears cellular H2O2 and other free radicals
to reduce cellular ROS (25). In this study we first examined
whether deletion of PrxII alters Ca2 signaling, osteoclasto-
FIGURE 1.Decreased bone density and increased [Ca2]i oscillations in PrxII
/mice. A, microradiograph
and histology (toluidine blue staining; scale bar, 50m) of tibiae fromWT and PrxII/mice at 8 weeks of age
(n  4). B, histological active bone formation of undecalcified tibiae bone from calcein-administered mice
(scale bar, 20 m). C, measurement of ROS production in WT and PrxII/ BMMs before and 48 h after RANKL
stimulation.D, oscillatory change in [Ca2]i inWT and PrxII
/ BMMs before and 48 h after RANKL stimulation.
The data were normalized to bone volume and ROS production inWTmice and expressed as themeans S.E.
*, p 0.01;, p 0.05 compared with WT.
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genesis, and bone remodeling and
its relation to ROS. To determine
the specific role of PrxII in oste-
oclastogenesis, the tibiae ofWT and
PrxII/ mice were dissected, and
bone density was measured by mi-
croradiographical and histological
analyses. The bone density of
PrxII/ tibiae was reduced by
31% compared with WT tibiae
(Fig. 1A).
To further analyze the effect of
PrxII deletion on bone formation,
we performed dynamic histomor-
phometric measurement on 4-week-
oldmice injected twice with calcein.
Osteoblast function was not influ-
enced by deletion of PrxII, as
reported by similar calcein labeling
(Fig. 1B). To determine the effect of
PrxII deletion on ROS and oste-
oclastogenesis, we measured intra-
cellular ROS in WT and PrxII/
BMMs. The level of ROS in BMMs
from PrxII/ mice was 2.5-fold
higher than in WT BMMs and did
not increase further upon 48 h of
treatment with RANKL (Fig. 1C).
RANKL controls osteoclastogen-
esis by induction of long lasting
Ca2 oscillations that starts 24–
48 h after RANKL treatment (see
below and Ref. 16). [Ca2]i oscilla-
tions inWTcellswere observed 48h
after RANKL treatment. By con-
trast, only spontaneous Ca2 oscil-
lations were observed in PrxII/
BMM cells, and most importantly,
neither the frequency nor the am-
plitude of the Ca2 oscillations was
affected by RANKL stimulation
(Fig. 1D).
To verify the chronic effects of
deleting PrxII on signaling and bone
homeostasis observed in the mice
and to develop an experimental
system to study the molecular char-
acteristics of the pathway linking
RANKL, ROS, Ca2 oscillations,
and osteoclastogenesis, we deter-
mined the effect of overexpressing a
dominant negative PrxII (DN-PrxII)
in RAW264.7 cells. Fig. 2A shows
that overexpression of DN-PrxII
caused an increase in the steady-
state level of ROS and induced
[Ca2]ioscillations in the absence of
RANKL stimulation, as was found
Hydrogen Peroxide Pathway in Osteoclastogenesis
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in BMMs obtained from the PrxII/mice. On the other hand,
overexpression of WT PrxII reduced the RANKL-evoked ROS
production and [Ca2]ioscillations (Fig. 2B).Hence, the in vitro
system recapitulates the effects observed in the PrxII/ mice
and indicates that deletion of PrxII causes a decrease in bone
density by inducing autonomous generation of ROS to induce
Ca2 oscillations that are similar to the RANKL-evoked Ca2
oscillations.
To further probe the signaling pathway linking RANKL and
ROS to osteoclastogenesis, we tested the role of Rac1, which
was reported to function upstream of receptor-mediated ROS
generation (26).We assayed the long term activation of Rac1 by
RANKL, at the timewhenRANKL-induced ROS activation and
Ca2 oscillations are observed. RANKL-mediated activation of
Rac1 is evident after 1 day and peaks after 2 days of stimulation
with RANKL (Fig. 2C). In parallel, the effect of a constitutively
active form of Rac1 (RacV12) was examined to determine
whether Rac1 is located upstream of and is involved in the gen-
eration of ROS and Ca2 oscillations. Expression of RacV12
resulted in an increased level of ROS production and in spon-
taneous Ca2 oscillations, equivalent to those induced by
RANKL stimulation (Fig. 2D). Moreover, the dominant nega-
tive form of Rac1 (RacN17) significantly inhibited RANKL-
stimulated ROS production and reduced the frequency of the
associated Ca2 oscillations (Fig. 2E).
RANKL-dependent and -independent Ca2 Oscillations
Require the Activation of PLC1, IP3-mediated Ca2 Release
and STIM1-regulated Ca2 Influx by SOC Channels—To
explore the pathway downstream of ROS that induces the Ca2
oscillations, we examined whether RANKL induces long term
activation of PLC1 (as revealed by PLC1 phosphorylation)
and the Ca2 transporting pathwaysmediating the oscillations.
First, we confirmed the phosphorylation of PLC1 that was
simultaneous with the generation of RANKL-induced Ca2
oscillations. PLC1 was phosphorylated after 1 day of RANKL
stimulation and remained phosphorylated for at least 2 days
(Fig. 3A). This is the first demonstration of long term activation
of PLC1 by RANKL. The essential role of PLC1 in RANKL-
induced Ca2 oscillations is shown by marked inhibition of the
oscillations in cells in which PLC1 was knocked down with
PLC1 siRNA (Fig. 3B).
To examine the role of PLC1 in RANKL-induced Ca2
oscillations in native cells, we tested the effect of inhibition of
PLC activity on the oscillations. Inhibition of PLC activity with
the PLC inhibitor U73122 inhibited RANKL-induced Ca2
oscillations in WT BMM cells. The inactive analogue U73343
had no effect (Fig. 3C). Importantly, the spontaneous Ca2
oscillations in BMMs from PrxII/mice are also inhibited by
inhibition of PLC (Fig. 3C), indicating that deletion of PrxII
resulted in sustained activation of PLC to induce the spontane-
ous long lasting Ca2 oscillations.
RANKL-induced [Ca2]i oscillations were examined next.
To probe the role of Ca2 release from the endoplasmic retic-
ulum (ER), cells were treated with the IP3 receptor inhibitor
Xest C. Acute inhibition of the IP3 receptors by 10 M Xest C
eliminated both the RANKL-induced and spontaneous Ca2
oscillations in BMMs fromWT and PrxII/mice (Fig. 4A).
Ca2 oscillations require a continued supply of Ca2 to re-
load the stores between Ca2 spikes. Potential Ca2 influx
channels can be the transient receptor potential (TRP) chan-
nels TRPM2 and TRPC3 that were reported to be activated
by ROS and nitric oxide, respectively (27, 28). However,
reverse transcription-PCR analysis revealed that RAW264.7
cells or BMMs do not express these channels (not shown).
Other Ca2 influx channels related to Ca2 oscillations are
FIGURE 2. Autonomous [Ca2]i oscillation by RANKL-independent generation of ROS and Rac1 activation via RANKL signaling pathway. A, effects of
DN-PrxII expression on ROS production and [Ca2]i oscillations in RAW264.7 cells (n  4). B, effects of PrxII overexpression ROS production and [Ca
2]i
oscillations in RAW264.7 cells (n  4). C, activation of Rac1 by RANKL in RAW246.7 cells probed with GTP-Rac1 (n  5). D, effect of the active form of Rac1
(RacV12) expression on ROS production and [Ca2]i oscillations in RAW264.7 cells (n 5). E, effects of dominant negative Rac1 (RacN17) expression on ROS
production and [Ca2]i oscillations in RAW264.7 cells (n 5). The data were normalized to ROS production in control cells transfected with green fluorescent
protein (GFP) and expressed as the means S.E. *, p 0.01;, p 0.05; **, p 0.005 compared with control cells.
FIGURE 3. Increased PLC1 phosphorylation and role of PLC in RANKL-
induced [Ca2]i oscillations. A, expression level of p-PLC1 and total PLC1
in BMMs of WT after RANKL stimulation (n  4). B, inhibition of RANKL-in-
duced [Ca2]i oscillations by knockdown of PLC1 (n 4). C, inhibitory effect
of RANKL-induced and spontaneous [Ca2]i oscillations in BMMs from WT
and PrxII/mice by the PLC inhibitor U73122 and lack of effect by the inac-
tive analogue U73343 (n 5). **, p 0.005 compared with control cells.
Hydrogen Peroxide Pathway in Osteoclastogenesis
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the SOCs, which are activated in response to Ca2 release
from the ER (29, 30). Indeed, the removal of extracellular
Ca2 and the SOC blocker Gd3 (1 M) rapidly terminated
both types of Ca2 oscillations (Fig. 4B). Recent work iden-
tified the ER-resident Ca2-binding protein STIM1 as the
ER Ca2 content sensor that conveys the ER Ca2 load to the
plasma membrane SOCs (25, 31). In response to Ca2
release from the ER, STIM1 clusters into punctae at the
ER/plasma membrane junctions, interacts with the SOCs,
and activates them (32, 33). To determine the role STIM1-
regulated SOCs in Ca2 oscillations, STIM1 was knocked
down with hSTIM1–1140 siRNA. Knockdown of STIM1
attenuated the RANKL-induced Ca2 oscillations in WT
BMMs and the spontaneous Ca2 oscillations in PrxII/
BMMs (Fig. 4C).
Long Term ROS Production by RANKL Mediates the Ca2
Oscillations and Regulates Osteoclast Differentiation via
PLC Activation—Ca2 oscilla-
tions appear only after 1 day of
stimulation with RANKL and last
for up to 3 days to allow completion
of osteoclastogenesis. If production
of ROS mediates the oscillations,
then RANKL-mediated ROS pro-
duction must persist for at least 3
days. We examined this prediction
by measuring the time course of
ROS production in response to
RANKL stimulation using 2,7-di-
chlorofluorescein diacetate fluores-
cence. RANKL-induced ROS pro-
duction is observed during 3 days
of RANKL stimulation (Fig. 5A).
These results are the first to show
that the time course of RANKL-in-
duced ROS production is similar to
the time course of RANKL-induced
Ca2 oscillations.
To test whether ROS produc-
tion is required only for induction
or also for sustaining the Ca2
oscillations, we determined the
effect of inhibiting ROS produc-
tion at different times before or
after RANKL stimulation. The
cells were either pretreated with
10 mM of the antioxidant NAC
for 30 min before RANKL stimula-
tion or exposed acutely to NAC
and to DPI, a NAD(P)H oxidase
inhibitor, during the oscillations.
No Ca2 response was observed
incells pretreatedwithNAC(Fig. 5B).
Moreover, exposing oscillating cells
to NAC or DPI inhibited ongoing
Ca2 oscillations (Fig. 5C), indicating
theneed for continuousROSproduc-
tion to sustain the oscillations.
The physiological role of long term ROS production was
studied by determining the effect of selective ROS scavenging
on activation of PLC1 and osteoclast differentiation. To deter-
mine whether the production of ROS is directly related to
PLC1 activation, osteoclast precursor cells were treated with
NAC and RANKL for 48 h. Scavenging ROS reduced PLC1
phosphorylation by 77 8.3% (Fig. 5D). Chronic scavenging of
ROS markedly reduced the 1- and 3-day RANKL-induced
osteoclast differentiations by 41.9  12%, as revealed by
reduction in the formation of multinucleated cells. Impor-
tantly, acute ROS scavenging, by 1 h of treatment with NAC
had no effect on the formation of multinucleated cells (Fig. 5,
E and F). Hence, the reported acute transient stimulation of
ROS production by RANKL (34) is not the ROS that medi-
ates the Ca2 oscillations and osteoclastogenesis. Rather, it
is the long term production of ROS that mediates the
osteoclastogenesis.
FIGURE 4. RANKL-induced and spontaneous [Ca2]i oscillations depend on Ca
2 release from the IP3
pool andCa2 influx by SOCs.A, RANKL-induced and spontaneous Ca2 oscillations inWT and PrxII/ BMM
cells are inhibited by inhibition of IP3-mediated Ca
2 release. B, dependence of [Ca2]i oscillations on extra-
cellular Ca2 in BMMs fromWT and PrxII/mice (n 5). C, knockdown of the ER Ca2 sensor STIM1 inhibits
[Ca2]i oscillations WT and PrxII
/ BMM cells.
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DISCUSSION
The RANK-RANKL cytokine system is the chief regulator
of osteoclastogenesis. RANKL stimulation activates a series
of mediators that are essential for differentiation of precur-
sor mononucleated cells into multinucleated osteoclasts
(35). These include activation of the Btk kinase that is asso-
ciated with activation of PLC1, TRAF6, and c-Fos to trigger
Ca2 oscillations that activate the calcineurin/NFATc1
transcription system and osteoclastogenesis. However, the
signals that are activated by RANKL to activate PLC1 and
how RANKL induces Ca2 oscillations are not known.
RANKL is a member of the TNF receptor family (36). Unique
to RANK and other TNF receptor is that they induce Ca2
oscillations only after long stimulation, with the oscillations
starting 24 h post-stimulation and lasting for more than
72 h (16, 18).
We found that RANKL stimulation induces a novel signaling
pathway that leads to generation of ROS and Ca2 oscillations
and is essential for osteoclastogenesis. The essential compo-
nents of the pathway are depicted in Fig. 6. Most notably, the
components of the pathway are all induced and activated after
24 h of RANKL stimulation and remain activated for 72 h or
longer. The most upstream component activated by RANKL
identified in the present study is the small G protein Rac1 (Fig.
2C). Strikingly, activation of Rac1 was sufficient to induce the
long term Ca2 oscillations and ROS production, indicating a
central role for Rac1 in RANKL signaling. Rac1 was also
reported to be required for the acute generation ROS observed
after 10 min of stimulation with epidermal growth factor in
epithelial cells (26). Whether the short term and long term
effects of Rac1 occur through the same pathway remains to be
determined. The long lasting activation of ROS by Rac1 may
involve ROS-induced ROS release (37). For example, serum
withdrawal was shown to trigger ROS-induced ROS release in
human 293T cells. Serum withdrawal leads to an immediate
mitochondria response and release ROS, which in turn acti-
vates the Rac1/Nox 1 pathway to generate ROS for 4–6 h (38).
This requires ROS-induced ROS release. Similarly, our findings
of activation of Rac1 by RANKL may mediate activation of
Nox1, which transiently generates intracellular ROS (26). This,
in turn, is likely to stimulate the mitochondria to cause sus-
tained ROS generation.
FIGURE 5. Sustained ROS production by RANKL-induced [Ca2]i oscillation and dependence of osteoclastogenesis on PLC1. A, measurements of ROS
production in RANKL stimulated WT BMMs. The results are expressed as the means  S.E. (n  5). B, inhibition of RANKL-induced [Ca2]i oscillations by
pretreatment with NAC, an inhibitor of ROS production. C, inhibition of RANKL-induced [Ca2]i oscillations by NAC and DPI, an inhibitor of NAD(P)H oxidase.
D, expression levels of p-PLC1 and PLC1 inWT BMMs in response to RANKL stimulation (n 4). E and F, RANKL-induced osteoclast differentiation in vitro in
WT BMMs (TRAP staining) (n 4). **, p 0.005 compared with RANKL-induced PLC1 phosphorylation.
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By virtue of ROS generation by the constitutively active Rac1,
the enzyme that regulates the ROS is downstream of Rac1. We
identified this enzyme as PrxII (Figs. 1 and 2). PrxII is a thiol-
based peroxide reductase that specifically clears cellular H2O2,
which indicates that the main ROS generated by RANKL is
H2O2. Overexpression of PrxII to scavenge the RANKL-gener-
ated H2O2 eliminated the RANKL-induced Ca2 oscillations.
Conversely, expression of dominant negative PrxII increased
ROS production and generated spontaneous Ca2 oscillations
(Fig. 2A). Furthermore, spontaneous Ca2 oscillations are
observed inBMMs isolated from thePrxII/mice (Fig. 1). The
Ca2 oscillations generated by the DN-PrxII and those ob-
served in PrxII/ BMMs have the same characteristics as the
Ca2 oscillations induced by RANKL in WT BMMs and
RAW264.7 cells.
In the next step in the pathway, the ROS generated by Rac1
leads to activation of PLC1. Indeed, inhibition of RANKL-
mediated ROS generation inhibits activation of PLC1 (Fig.
5D), placing activation of PLC1 downstream of ROS genera-
tion. Although activation of PLC1 by RANKL was reported
before (20), the activation was transient and occurred during
the first 1 h of RANKL stimulation, long before Ca2 oscilla-
tions ensue. The role of the acute activation of PLC1 by
RANKL is not known at present. Here we show that RANKL
stimulation activates PLC1 after 24–72 h. The long term acti-
vation of PLC1 is required for the generation of Ca2 oscilla-
tions because knockdown of PLC1 almost completely inhib-
ited the RANKL-induced Ca2 oscillations. In addition, the
persistent activation of PLC1 is required tomaintain the oscil-
lations, because inhibition of cellular PLC activity with the pan
PLC inhibitor U73122 halted ongoing Ca2 oscillations
induced by RANKL (Fig. 3).
The long term and persistent activation of PLC1 leads to
generation of Ca2 oscillations. The oscillations required Ca2
release from internal stores, as revealed by their inhibition by
the IP3 receptors inhibitor Xest C. Sustaining the Ca2 oscilla-
tions requires Ca2 influx through SOCs. This is concluded
from inhibition of the oscillations by removal of extracellular
Ca2 and by knockdown of STIM1 (Fig. 4). STIM1 is the sensor
of the ER Ca2 content that clusters in response to depletion of
ER Ca2 and activates all type of SOCs (31, 39).
The sustained RANKL-induced Ca2 oscillations lead to
activation of NFATc1 and osteoclast differentiation (16, 40) to
mediate bone remodeling. The crucial physiological roles of the
RANKL-induced and activated ROS pathway in osteoclasto-
genesis and bone remodeling is demonstrated by the marked
reduction in bone density observed in the PrxII/mouse (Fig.
1). Strikingly, BMMs from PrxII/ mice showed higher
steady-state ROS levels than their WT counterpart and dis-
played autonomous Ca2 oscillations in the absence of RANKL
stimulation. These BMMs are expected to lead to increased
osteoclast differentiation and thus reduced bone density.
Indeed, scavenging ROS markedly reduced RANKL-induced
osteoclastogenesis (Fig. 5E).
In summary, the RANK/RANKL-mediated osteoclastogen-
esis and bone remodeling are complex processes that involve
activation of several signaling pathways. RANKL recruits
TRAF6 to activate NF-B and the JNK pathways (13–15) and
activates c-Fos and AP-1 (16), all of which are required for the
induction of NFATc1 (41–43) (Fig. 6). Once induced, NFATc1
is activated by dephosphorylation that ismediated by theCa2-
activated phosphatase calcineurin. The present studies identi-
fied a ROS-generating pathway that is induced by RANKL to
evoke Ca2 oscillations, which start24 h after RANKL stim-
ulation and last for more than 72 h, probably until completion
of osteoclastogenesis and bone remodeling. The ROS pathway
is recognized to play a role in an increasing number of physio-
logical functions (44–46). Manipulation of this pathway may
offer a target for treatment of bone-related diseases, such as
osteoporosis and osteomalacia. At the same time, consider-
ation of the altered ROS pathway for treatment of other dis-
eases must take into account the critical role of the ROS in
RANKL-mediated signaling and bone metabolism.
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